Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award

Posted on by Phenomenological Research Awards

Dr. Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award 

Medical Oncologist at Hospital 12 de Octubre | Spain

Dr. Javier Baena Espinar is a prominent medical oncology researcher whose work has significantly shaped contemporary understanding of thoracic malignancies, precision oncology, and real-world clinical outcomes. His academic background is grounded in advanced training in health sciences, biomedicine, molecular oncology, immuno-oncology, and cancer biology, supported by multiple postgraduate degrees and specialized certifications that have strengthened his expertise in lung cancer research and evidence-based clinical practice. His professional experience spans leading Spanish healthcare and research institutions, where he has contributed to multidisciplinary oncology teams, national research initiatives, and international collaborative networks focused on improving diagnostic accuracy, treatment personalization, and therapeutic decision-making. His research interests center on non-small cell lung cancer, small cell lung cancer, immune checkpoint inhibitors, next-generation sequencing, biomarker discovery, outcomes research, and the intersection between cancer care and infectious disease vulnerabilities. He has been instrumental in studies evaluating immunotherapy effectiveness, prognostic determinants, molecular profiling, and global registry data, producing findings that support the optimization of treatment strategies and guide clinical standards. With 27 published documents, 884 citations from 800 referencing articles, and an h-index of 11, his scholarly contributions reflect sustained impact and influence across oncology and translational research communities. His work appears in high-impact journals and encompasses both clinical and translational dimensions, bridging innovative scientific methodologies with real-world applicability. Through continuous involvement in international collaborations, multicenter studies, and academic dissemination, he has advanced the understanding of patient outcomes, therapeutic safety, and emerging frontiers in cancer treatment. His research trajectory demonstrates a strong commitment to expanding precision medicine, fostering collaborative research excellence, and improving the clinical management of thoracic cancers. Dr. Javier Baena Espinar’s ongoing contributions highlight his dedication to advancing scientific knowledge, strengthening global oncology evidence, and supporting the evolution of patient-centered cancer care.

Profile: Scopus | Orcid

Featured Publications:

  • Baena Espinar, J. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first-line pembrolizumab outside clinical trials: Pembro-real 5Y registry results. Journal for Immunotherapy of Cancer.

  • Baena Espinar, J., et al. (2025). Clinical utility of combined tissue and plasma next-generation sequencing in treatment-naïve advanced NSCLC. JTO Clinical and Research Reports.

  • Baena Espinar, J., et al. (2025). Efficacy and safety of lorlatinib in ALK- and ROS1-rearranged metastatic NSCLC within the compassionate use program in Spain.

  • Baena Espinar, J., et al. (2025). Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in lung cancer patients.

  • Baena Espinar, J., et al. (2025). Safety and efficacy of immune checkpoint therapy in patients with cardiac metastasis: A multicenter international retrospective analysis.

  • Baena Espinar, J., et al. (2025). Unmet needs in maintenance therapy for extensive-stage small cell lung cancer.

  • Baena Espinar, J. (2024). Consolidation osimertinib vs durvalumab vs observation after chemoradiation in unresectable EGFR-mutant NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Real-world data of first-line cemiplimab monotherapy for PD-L1 high NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage SCLC. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Targeting KRAS G12C in NSCLC: Current standards and developments. Drugs.

  • Baena Espinar, J.(2023). Future perspectives in second-line therapy for non-oncogene–addicted NSCLC. Cancers.

  • Baena Espinar, J. (2023). Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer. Journal of Clinical Oncology.

  • Baena Espinar, J.(2022). Updated prognostication system for thoracic malignancies with COVID-19: TERAVOLT registry. Journal of Thoracic Oncology.

  • Baena Espinar, J. (2022). COVID-19 outcomes, vaccination status, and cancer-related delays during the Omicron wave: TERAVOLT analysis. JTO Clinical and Research Reports.

Inesh Sood | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research Awards

Mr. Inesh Sood | Medicine and Dentistry | Best Researcher Award

Research Intern at University of Oxford | United Kingdom

Mr. Inesh Sood is an accomplished medical scholar and emerging researcher from the University of Oxford, whose work bridges medicine, neuroscience, and technological innovation. With a First-Class Honours degree in Medical Sciences and ongoing studies toward the Bachelor of Medicine and Bachelor of Surgery, he has consistently demonstrated academic excellence, earning top distinctions and merit-based scholarships. His education has been characterized by a rigorous engagement with clinical sciences, biomedical research, and leadership in academic societies, notably through his service as Vice-President of a prominent medical society at Oxford. Professionally, he has contributed to cutting-edge research projects within the Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, where he evaluated the application of artificial intelligence scribes in clinical consultations, exploring how technology can enhance medical efficiency and patient care. In parallel, his work with the Bajo Lorenzana Auditory Neuroscience Group focuses on the optogenetic activation of neuronal pathways, where he developed MATLAB-based analytical tools to assess and classify neuronal activity from live recordings an initiative that demonstrates his technical proficiency and innovative approach to neuroscience research. His findings are being presented at the prestigious Society for Neuroscience (SFN) conference, underscoring his growing recognition within the global scientific community. Earlier, as a visiting scholar at Brown University, he conducted molecular and cell biology research on germline migration using CRISPRCAS9 techniques and single-cell sequencing analysis, contributing to publications in developmental biology. Beyond his laboratory expertise, he has also engaged in healthcare consulting, applying analytical and strategic thinking to support biotech innovation in cancer vaccine development. His diverse skill set spans biomedical research, data analysis, and leadership in academic and collaborative settings. Mr.Inesh Sood’s research interests lie in medical innovation, neuroscience, and the intersection of artificial intelligence with healthcare systems. Through his interdisciplinary experiences, he continues to pursue a vision of advancing scientific discovery and improving patient outcomes by combining evidence-based medicine with cutting-edge technology, reflecting a commitment to excellence, curiosity, and societal impact in the field of medicine and dentistry.

Profile: Orcid | LInkedin

Featured Publications:

H., Sood,(2025).Biomarkers in Stereotactic Ablative Radiotherapy: Current Evidence and Future Directions. International Journal of Molecular Sciences, 26(21), 10640.

H., Sood,(2025).Emerging Applications of Stereotactic Ablative Radiotherapy in Oligometastatic Colorectal Cancer. International Journal of Molecular Sciences, 26(21), 10302.